The GLP-1 weight-loss boom created a parallel pharmacy ecosystem that did not exist three years ago. Roughly 12% of American adults have now tried a GLP-1 agonist — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or liraglutide (Saxenda) — and most of them got the prescription through a telehealth provider rather than a primary-care visit.01 The reason is simple: insurance coverage for weight-loss indications is patchy and brand-name cash prices are punishing. A self-pay patient looking at $1,349/month for brand Wegovy02 will, reasonably, hunt for a cheaper path.
That hunt now lands on roughly two dozen direct-to-consumer GLP-1 telehealth brands. The pricing spreads are wide. The compounding regulations shifted sharply in late 2024 when the FDA declared the official semaglutide shortage resolved.03 The clinical quality varies. We tested ten of the largest providers and ranked them on six fixed metrics. Three failed our pharmacy-sourcing audit and are flagged below. The rest split into three clear tiers: brand-name-only with full clinical infrastructure (Ro, PlushCare), compounded at scale with adequate oversight (Hims, Henry Meds, Mochi, Eden, Form), and coaching-led programs that bolt medication onto a behavior-change product (WeightWatchers Clinic, Calibrate).
01 / 08How GLP-1 telehealth actually works in 2026
A typical telehealth GLP-1 program follows a four-step pipeline. You complete an asynchronous medical-history questionnaire (height, weight, BMI, comorbidities, current medications, allergies). A licensed clinician — physician, nurse practitioner, or physician assistant, depending on the provider and state — reviews your intake either asynchronously or via a brief video call. If you meet eligibility (typically BMI ≥ 27 with a comorbidity, or BMI ≥ 30 without), a prescription is sent to either the provider's preferred 503A compounding pharmacy or a major retail pharmacy, depending on which medication you were prescribed. Refills run on a monthly or bi-monthly auto-ship cadence with periodic check-ins.
The compounded-vs-brand split is the dominant pricing axis. Brand-name Wegovy and Zepbound, cash-pay, run roughly $1,000–$1,400 per month depending on dose and the pharmacy. Compounded semaglutide via telehealth runs $196–$297. The difference is not the active ingredient — both contain semaglutide — but the manufacturing source, regulatory pathway, and clinical defensibility. We score them as different product categories, not different prices on the same product.
02 / 08The 2026 pricing landscape
Below is our full pricing audit. All figures are real charges from our test purchases in April–May 2026. Monthly pricing assumes a titration-step dose (most providers use a graduated schedule starting at 0.25 mg semaglutide weekly and increasing to 2.4 mg over 16+ weeks).
| Provider | Medication | Consult fee | Monthly cost | Annual cost |
|---|---|---|---|---|
| Ro Body | Brand Wegovy / Zepbound | $99 included | $1,000+ | $12,000+ |
| PlushCare | Brand only via insurance | $99/mo membership | $1,349 | $17,287 |
| Hims (brand) | Brand Wegovy | $0 with subscription | $499 | $5,988 |
| Mochi Health | Compounded semaglutide | $0 with subscription | $279 | $3,348 |
| Henry Meds | Compounded semaglutide | $0 with subscription | $297 | $3,564 |
| Form Health | Compounded + brand options | $99/mo program | $249 + program | $4,176 |
| Hims (compound) | Compounded semaglutide | $0 with subscription | $199 | $2,388 |
| Eden | Compounded semaglutide | $0 with subscription | $196 | $2,352 |
| Lemonaid Health | Brand via pharmacy | $95 / visit | varies (brand cash) | $13,000+ |
| WW Clinic + medication | Brand only | $99/mo program | $1,188 + program | $15,444 |
| Calibrate + medication | Brand only (insurance-led) | $129/mo program | copay + program | $1,548–$15,000 |
The spread is bracingly wide. The cheapest legitimate program (Eden, $196/mo compounded) costs roughly one-sixth of the most expensive (PlushCare's full brand cash, $1,349/mo). Coaching-led programs (WW Clinic, Calibrate) add a $99–$129/mo program fee on top of medication, which is rational if you want behavior-change support but costly if you only want the prescription.
Your 12 months on a GLP-1 will cost between $2,352 and $17,287.
| Path | Monthly | 12-month total |
|---|---|---|
| PlushCare full brand cashNo insurance, brand Wegovy | $1,349 | $17,287 |
| WW Clinic + brand cashProgram + medication, no insurance | $1,287 | $15,444 |
| Lemonaid + brand at retail$95 consult + GoodRx Wegovy | $1,083 | $13,000 |
| Ro Body brand WegovyIf Ro's pharmacy negotiation lands | $1,000 | $12,000 |
| Hims brand WegovyCheapest brand path we found | $499 | $5,988 |
| Form Health compound + program$99 program + $249 medication | $348 | $4,176 |
| Henry Meds compoundedMicro-dose protocol included | $297 | $3,564 |
| Mochi compoundedStandard titration | $279 | $3,348 |
| Hims compoundedCheapest mass-market option | $199 | $2,388 |
| Eden compoundedLowest 12-month cost we found | $196 | $2,352 |
If you want the brand-name product specifically — because your insurance will reimburse, because you tolerate the brand's titration schedule better, or because the regulatory clarity matters to you — your cheapest legitimate route is Hims at $499/month. If you can use a compounded product, Eden at $196 is the cheapest provider that also passed our pharmacy audit.
03 / 08Ro Body — best brand-name access
Ro is the most clinically infrastructured of the GLP-1 telehealth providers. The Body program (their weight-loss arm) is integrated with their broader telehealth practice, which means the clinician reviewing your case is the same network seeing your erectile-dysfunction, hair-loss, and cardiometabolic patients. The intake is more rigorous than the compound-only competitors — Ro requires recent labs, complete medication reconciliation, and a video visit for new GLP-1 patients in most states.04
Strongest clinical infrastructure for brand-name Wegovy / Zepbound.
Ro doesn't compound, which is a feature, not a bug, post-FDA-shortage. The Body program's pharmacy connections give cash-pay patients the strongest brand-name access we tested. The catch: cash-pay brand pricing is still ~$1,000/month. Worth it if your insurance reimburses, or if you need the regulatory clarity of brand-name product.
04 / 08Hims — best compounded value at scale
Hims pivoted aggressively into the compounded-GLP-1 market in 2024 and rapidly became the largest single distributor by volume. As of our May 2026 audit, Hims offers two distinct GLP-1 tracks: a compounded semaglutide subscription at $199/month and a brand Wegovy track at $499/month (sourced through retail pharmacy partners). The compounded line is sourced from a single 503A pharmacy partner that passed our state-board verification.
The best price-to-clinical-floor ratio in compounded GLP-1.
Hims's compounded line at $199/mo is genuinely competitive — and at this scale, their pharmacy sourcing has more public visibility than most. Brand-name access at $499/mo is the cheapest legit brand-Wegovy path we found. Where Hims loses points: the intake is lightweight (asynchronous-only in most states), labs are optional, and the clinical follow-up cadence is shallow compared to Ro or Henry.
Compare compounded GLP-1 prices across all 10 providers
We refresh this comparison monthly. The pricing surface moves fast — providers reshuffle subscription tiers, pharmacy partners change, and consult fees come and go.
05 / 08Henry Meds — best clinical depth
Henry Meds was one of the earliest movers in compounded semaglutide and built its reputation on the micro-dosing protocol — pre-titration doses below the lowest commercial step (0.1 mg, 0.15 mg, 0.2 mg semaglutide weekly) for patients with high sensitivity to GI side effects. That same clinical rigor extends to the rest of the intake: required labs, mandatory video visits in most states, and a slower titration schedule than the mass-market competitors.05
The most clinically defensible compounded option.
$297/mo is more than Hims or Eden, but you're paying for genuine clinical oversight: required labs, real video visits, and a micro-dosing protocol that gives Henry a regulatory leg-to-stand-on in the post-shortage environment. If you're side-effect sensitive or have a comorbidity, Henry is the right pick over the cheaper alternatives.
06 / 08WeightWatchers Clinic + Calibrate — coaching-led
WeightWatchers Clinic (the rebranded Sequence acquisition) and Calibrate represent a fundamentally different product category. They are behavior-change programs that include medication, not medication programs that include coaching. Both charge a separate program fee — WW Clinic at $99/month, Calibrate at $129/month — on top of medication costs, and both lean heavily on brand-name prescribing (Wegovy, Zepbound) rather than compounded products.06
- Brand-name Wegovy / Zepbound
- Cancel monthly, no annual lock-in
- Integrates with WeightWatchers app
- Insurance-friendly, will help with appeals
- Total cost varies wildly with insurance
- 12-month program contract typical
- Brand-name only, insurance-leaning
- Deeper behavior-coaching curriculum
- Outcome guarantee with caveats
- Premium price for premium structure
For patients with employer insurance that covers GLP-1s for weight-loss indications, both programs become roughly cost-equivalent to a primary-care visit plus medication copay — and the coaching genuinely improves adherence in published data.07 For self-pay patients, the program fee is hard to justify on top of $1,000+/mo medication cost. The cheaper compounded path through Hims or Eden, paired with separate (free or low-cost) behavior coaching, is usually the more rational play.
A telehealth GLP-1 program is not a drug. It's a clinical workflow wrapped around a drug. The drug costs about the same everywhere. The workflow is what varies — by tenfold. — Dr. Priya Shah, PharmD · RxGrab editorial review
07 / 08Mochi + Eden + Form Health — the emerging tier
Three more providers deserve specific mention. Mochi Health ($279/mo compounded) is the venture-capital-backed challenger to Hims, with a more polished member experience and a stronger emphasis on women's health framing. Their pharmacy sourcing passed our audit. Eden ($196/mo compounded) is the cheapest legitimate option in our test, with a no-frills product and adequate clinical oversight — appropriate for a price-sensitive patient who's comfortable with an asynchronous intake. Form Health ($99/mo program + $249/mo medication) sits between the cheap-compound and coaching-led tiers, bundling clinician oversight with optional brand or compound paths.
Two providers we don't recommend by name failed our pharmacy-sourcing audit and we list them by category only. Both were sourcing compounded semaglutide from 503A pharmacies with documented state-board sanctions in the prior 24 months. The cost savings versus Eden or Hims is not worth the regulatory risk.
Six metrics, same weight, no exceptions.
We score every GLP-1 telehealth provider on the same six metrics, weight them equally on a 10-point scale, and publish what failed alongside what won. Read the full methodology →
Monthly Price
Total monthly cost including consult, subscription, and medication.
Pharmacy Audit
503A licensing verified on state pharmacy board record.
Clinical Floor
Required labs, intake depth, follow-up cadence.
Wait Time
Intake-to-prescription latency in business days.
Cancellation
How easy it is to leave, refund policy, lock-in periods.
Transparency
Public pricing, named clinicians, named pharmacy partners.
08 / 08Who should skip telehealth GLP-1s entirely
Three groups should not be using a direct-to-consumer telehealth GLP-1 program in 2026. One: patients with type 2 diabetes who already have a primary-care relationship — your endocrinologist or PCP can prescribe Ozempic on-label, your insurance will reimburse, and your copay structure will almost always beat any cash-pay telehealth path. Two: patients with employer insurance that covers Wegovy for weight-loss indications — go through your insurance, do not pay cash for compounded product to save your insurer money. Three: patients with active eating disorders, severe gastroparesis, personal or family history of medullary thyroid carcinoma, or pregnancy — these are absolute or relative contraindications and need a real in-person workup, not a 5-minute asynchronous questionnaire.08
For everyone else — the 80%+ of GLP-1-curious patients who don't fit those exclusions — the telehealth path is real, the prices range tenfold, and the editorial picks above represent honest tradeoffs between price, clinical depth, and regulatory defensibility.